Recovering Hearts. Saving Lives.

Transcription

1 Recovering Hearts. Saving Lives ṬM Michael Minogue Chairman, President, & CEO

2 LEGAL DISCLAIMERS 2 This presentation contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities, the Company s guidance for future financial performance and expected regulatory approvals. Each forward-looking statement contained in this presentation is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statement, including uncertainties associated with development, testing and related regulatory approvals; the potential for future losses; the impact of complex manufacturing processes and high quality requirements; dependence on limited sources of supply; competition; technological change; government regulation; third-party reimbursement to the Company s customers; litigation matters; future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this presentation or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or otherwise, unless otherwise required by law. U.S. Food and Drug Administration Approvals The Impella 2.5 System is a temporary ( 6 hours) ventricular support device indicated for use during high risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction, when a heart team, including a cardiac surgeon, has determined high risk PCI is the appropriate therapeutic option. Use of the Impella 2.5 System in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri- and post-procedural adverse events. The Impella2.5, Impella CP, Impella 5.0, and Impella LD Catheters, in conjunction with the Automated Impella Controller (collectively, "Impella System Therapy"), are temporary ventricular support devices intended for short term use ( 4 days for the Impella 2.5 and Impella CP, and 6 days for the Impella 5.0, and Impella LD) and indicated for the treatment of ongoing cardiogenic shock that occurs immediately (< 48 hours) following acute myocardial infarction or open heart surgery as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures (including volume loading and use of pressors and inotropes, with or without IABP). The intent of the Impella System Therapy is to reduce ventricular work and to provide the circulatory support necessary to allow heart recovery and early assessment of residual myocardial function. The Impella RP is indicated for providing circulatory assistance for up to 14 days in pediatric or adult patients with a body surface area 1.5 m2 who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery. For safety information associated with Abiomed s technologies, visit and Impella ECP TM, Impella CP Next Generation, Impella 5.5 TM, Impella BTR TM, The Impella Pediatric TM, and Symphony are in development and are not approved for use or sale. The ABIOMED logo, ABIOMED, Impella CP, Impella RP and Symphony are registered trademarks of Abiomed, Inc. in the U.S.A. and certain foreign countries. Impella 2.5, Impella 5.0, Impella LD, Impella BTR, Impella cvad, Impella ECP and Recovering hearts. Saving lives. is a trademark of Abiomed, Inc.

3 THE ABIOMED MISSION 3 Providing percutaneous heart support technologies for high risk patients to enable safer, more complete minimally invasive procedures, recover heart muscle and provide cost-effective patient care

4 PERCUTANEOUS, PMA-APPROVED TECHNOLOGIES 4 PLUMBING ELECTRICITY VALVE PUMP Stents/PCI 2 Pacemaker / ICDs Edwards TAVR Impella CY 2015 Units/Patients per year in U.S. 1 > 1 Million ~400,000 ~19,000 ~10, ACC/AHA 2015 Heart Disease and Stroke Statistics 2015 Update & Respective company websites and Leerink and William Blair analyst models 2. Percutaneous Coronary Intervention.

5 IMPELLA HEART PUMP: THE NEW STANDARD OF CARE 5 Outflow Inflow 1976: IABP FDA 510(k) 2014: Routine use of IABP in patients with cardiogenic shock is not recommended (Class III=Harmful) : Impella 2.5 TM FDA 510(k) 2015: FDA PMA Approval for High Risk PCI : FDA PMA Approval for Cardiogenic Shock 2 IABP=Intra aortic Balloon Pump 1. European Guidelines: European Heart Journal 2. High-Risk PCI PMA Approval for Impella 2.5. Cardiogenic Shock PMA Approval for all left heart Impella devices (2.5, CP, 5.0, LD)

6 THE ABIOMED STORY 6 1. Impella heart pumps are a breakthrough percutaneous platform 2. Addressing a clinical need for a large patient population 3. The new standard of care in a $2 billion market

7 IMPELLA HEART PUMP: A BREAKTHROUGH TECHNOLOGY 7 FDA approvals: Safe & Effective PMA for High Risk PCI (Impella 2.5 TM ) and Cardiogenic Shock (all left-side devices); HDE approved (Impella RP ) DRG 215 / 268 / U.S. hospitals, treating 40,000+ U.S. patients 254 patents & 220 patents pending

8 THE HEMODYNAMIC SUPPORT OF IMPELLA HEART PUMPS 8 Unloads & Rests the Heart Muscle Impella 2.5 On Maintains Arterial Pressure 1 Enables High Risk Cath Lab Procedures MAP 110 mmhg -8% -10% -12% Outflow MAP 86 mmhg 97 mmhg -15% -23% -51% Inflow Impella + Case Start Balloon Inflation 15 sec 30 sec 45 sec 42 mmhg = Protected PCI TM 1. Simulated Tracing: Physiologic computational modeling, Am J Physiol 1991;260 (HCP 29): H146-H157

9 EXPANDING THE IMPELLA HEART PUMP PLATFORM 9 Femoral Insertion Axillary Insertion AIC (Automated Impella Controller) TM Impella 2.5 TM Impella 5.0 TM / LD TM Impella CP Venous Insertion Impella RP

10 THE ABIOMED STORY Impella heart pumps are a breakthrough percutaneous platform 2. Addressing a clinical need for a large patient population 3. The new standard of care in a $2 billion market

11 ADDRESSING A SIGNIFICANT CLINICAL NEED: CORONARY ARTERY DISEASE (CAD) & HEART FAILURE 1 11 #1 Cause of Death in U.S.: Coronary Artery Disease #1 Risk Factor: Ejection Fraction #1 Mortality Risk in Hospital: Cardiogenic Shock #1 Health Expenditures: Heart Conditions ($204B) stories-of-heart-disease-patients 1. American Heart Association: Heart Disease and Stroke Statistics 2015 Update

12 TREATING THE HIGH RISK HEART FAILURE POPULATION 12 Drug Therapy / Home / Hospice Care (Likely Surgical Turndown): Surgical Suite (Sternotomy): Cath Lab: New Treatment Option with Impella

13 HIGH RISK HEART FAILURE POPULATION GROWING 13 Protected PCI TM Hemodynamic Instability Elective Urgent Emergent

14 6% PENETRATION TODAY 20% YIELDS $1.0B IN U.S. 14 U.S. Annual Number of High Risk Patients (TAM): Protected PCI 1 TM 121,000 (Elective + Urgent) 221,000 Emergent 2 100,000 20% penetration = 44k patients = $1.0B Right-side Failure 3 4,000 Impella RP Patients Rest of World 4,5 50,000 in Japan 20,000 in Germany 1) American Heart Association, Heart Disease and Stroke Statistics 2015 Update ; Gheorghiade et al Circulation, ; Braunwald, et al. JACC ; Dehmer, et al. JACC 2012 ; Eric Peterson_nejm_2010 ; JAMA, Cornwell ; Farmer SA, JACC. Cardiovascular imaging. Jul Truven Analysis, in Press 2) HRI 2015: Cardiogenic Shock ; and American Heart Association, 2015 Statistics 3) Right heart failure from AMI RV infarct, respiratory issues, LVAD, failed transplant: HRI 2009 Report, ISHLT, Intermacs. 4,000 patient population cap per the HDE Approval 4) Japan, pending PMDA approval. IABP usage with PCI and AMI, 2009 report on Catheter, Tube, & Interventional Device ; About 40% of PCI was for AMI, Coronary Stent survey by PMDA. 5) Widimsky et al, European Heart Journal (2010)

15 HEART MUSCLE RECOVERY IS OUR MISSION Protected PCI TM Emergent / Cardiogenic Shock Other Right-Side Support Protected VT Ablation (EP Lab) 1 1. Impella s use during VT Ablation is not PMA Approved.

16 THE ABIOMED STORY Impella heart pumps are a breakthrough percutaneous platform 2. Addressing a clinical need for a large patient population 3. The new standard of care in a $2 billion market

17 NEW HIGH RISK PCI INDICATION APPROVED BY FDA MARCH 23, 2015 Impella

18 MACCE (%) IMPELLA 2.5 TM HEART PUMP REDUCES PERI & POST PROCEDURAL MACCE MACCE = Death, Stroke, MI, Repeat revasc IABP N=211 29% reduction in MACCE 15 Impella 2.5 TM N= MACCE, Major Adverse Cardiac and Cerebrovascular Event, defined as death, stroke, MI, repeat revascularization Dangas et al, Am. Journ of Cardiol. 2014: 113(2):222-8 Time Post Procedure (days) FDA Randomized Controlled Trial: Protect II p=0.042

19 NEW CARDIOGENIC SHOCK INDICATION APPROVED BY FDA APRIL 7, Impella is the only percutaneous heart pump proven safe and effective for hemodynamic stabilization to enable Heart Recovery Indications now include Protected PCI and Cardiogenic Shock in the setting of AMI and Postcardiotomy The Impella heart pumps stabilize the patient's hemodynamics, unload the left ventricle, perfuse the end organs and allow for recovery of the native heart. The intent of the Impella system therapy is to reduce ventricular work and to provide the circulatory support necessary to allow heart recovery and early assessment of residual myocardial function.

20 IMPELLA RP FOR RIGHT HEART SUPPORT APPROVED BY FDA JANUARY 25, Impella RP Bi-Ventricular Support The Impella RP is designed to provide the flow and pressure needed to compensate for right heart failure. The device does not require a surgical procedure for insertion, and it provides up to four liters per minute of hemodynamic support

21 IMPELLA HEART PUMP: THE NEW STANDARD OF CARE 21 Clinical Society Guidelines: 7 Sets, >380 Publications Quality of Life and Cost Effectiveness: Multiple Publications Established Reimbursement (DRG 215 / 268 / 269) Hospital, Physician, Insurer Standardization * Slides In Appendix 3 FDA Approvals for Impella Devices* High-Risk PCI, Cardiogenic Shock, Right Heart Support * High-Risk PCI FDA PMA Approval for Impella 2.5. Cardiogenic Shock FDA PMA Approval for all left heart Impella devices (2.5, CP, 5.0, LD). FDA HDE Approval for the Impella RP

22 IMPELLA HEART PUMPS ALIGN WITH HEALTHCARE REFORM 22 Improves Quality of Life: Reduction of Class III and IV Heart Failure: 58% 1, 52% 2 Improves Quality of Life: Heart ejection fraction increase of 32% 3, 31% 4, 22% 1, 17% 2, 13% 5 Reduces Mortality*: Use of short-term MCS in the United States has increased rapidly, whereas rates of in-hospital mortality have decreased 6 Hemodynamic support demonstrates significantly reduced mortality with PVADs when compared to IABP in patients undergoing PCI 18 Is Cost-Effective: Declining hospital costs (Cost Reduction $45k and $54k per case in AMI and CAD) 6 Reduces hospital length of stay 8,9,11,12,13,14,15,16,17 Reduces expensive hospital readmission costs 11 Creates minimal impact on payer s budget O Neill et al, Circulation. PROTECT II, Maini et al, Journal of American College of Cardiology (abstract). USPella, Burzotta et al J Card Med, Dixon et al. Journal of American College of Cardiology Interv. PROTECT I, Sjauw et al. Journal of American College of Cardiology. MACH 2, Stretch et al, Journal of the American College of Cardiology, Lemaire et al, Annals of Thoracic Surgery, O Neill et al, Journal of American College of Cardiology. USPella, Maini et al,journal of Catheterization and Cardiovascular Interventions, Maini et al, Expert Review Pharmaeconomics & Outcomes Research, Roos et al, Journal of Medical Economics, Gregory et al, American Health & Drug Benefits Journal, Gregory et al, Journal of Managed Care Medicine, Krenn et al, SCAI, Aryana et al, Heart Rhythm Society, Wohns et al. International Society for Minimally Invasive Cardiothoracic Surgery, Lamarche et al. Journal of Thoracic and Cardiovascular Surgery, Patel et al. Journal of Interventional Cardiology, 2015

23 ABIOMED PRIORITIZATION OF GLOBAL MARKET OPPORTUNITY 23 United States 1,000+ Hospitals 200+ Field Reps in U.S. On-site expert support in hospital Japan: Dedicated Team ; Reimbursement Pending Germany: Dedicated Team 24 x 7 Clinical phone support Impella Product Penetration in U.S. Heart Hospitals (%): Impella Products Approved ; Key Market, Direct Distribution/Coverage Impella Products Approved and Zero to Limited Coverage

24 MANUFACTURING EXPANDING WITHIN DANVERS AND AACHEN FACILITIES 22 Danvers, MA Aachen, Germany Expansion: 79,000 sq.ft. to 163,000 sq.ft. Expansion: 33,000 sq.ft. to 71,000 sq.ft.

25 FY 2017 Guidance: STRONG REVENUE GROWTH & GROSS MARGIN (~84%) 43% 32-35% $ M 25 Abiomed Total Revenue ($M) FY: April-March 25% $330 16% 48% 38 Impella Acquisition 14% 44 16% 51 16% k 24% 73 17% 86 18% st Profitable Year 25% % FDA Approval Protected PCI FDA Approval Cardiogenic Shock FY 05* FY 06 FY 07 FY 08 FY 09 FY 10 FY 11 FY 12 FY 13 FY 14 FY 15 FY 16 FY 17E Founded 1981, Headquartered in Massachusetts, * New Management, Fiscal year 2005

26 POSITIVE CASH FLOW & STRONG BALANCE SHEET 26 GAAP Operating Income ($M) 1 Debt: $0 $65.8 Deferred Tax Asset 1 : $45 Million $28.7 Cash ($M) 2 $213 $237 FY 10 FY 11 $1.5 FY 12 $16.5 $8.4 FY 13 FY 14 FY 15 FY 16 $60 $77 $88 $118 $146 ($11.2) ($25.1) FY 11 FY 12 FY 13 FY 14 FY 15 FY 16 Q GAAP net income for fiscal year 2015 was $113.7 million included an income tax benefit of the $86.5million. This was a result of the Q4 FY15 release of the valuation allowance of most deferred tax assets. The release of the valuation allowance was a onetime accounting adjustment with the offset recorded on the balance sheet as short and long term deferred tax assets based on the Company's estimates of sustainable profitability. 2. Cash, cash equivalents, short and long term marketable securities

27 FUTURE POPULATION HEART ATTACK : STEMI INFARCT REDUCTION OPPORTUNITY 26 Large Infarcts Driving Growing Epidemic of Heart Failure: Within 5 years of 1st Myocardial Infarction, 36% of men and 47% of women will die 1 76% 39% Infarct After Reperfusion Injury* *Myocardial damage at the cellular/ mitochondrial level rmal 10% 14% Ezekowitz JA et al JACC 2009 Kapur et al JACC 2015 * Impella is not approved for STEMI patients. STEMI is a future potential patient population 1. American Heart Association Statistics, 2015

28 IMPELLA PLATFORM: A LONG RUN-WAY FOR GROWTH 28 Products Impella 2.5 TM Impella CP Impella 5.0 TM Impella RP HDE Impella ECP TM Impella 5.5 TM Impella BTR TM Wearable Driver Indications Protected PCI TM Cardiogenic Shock Right-Side & Left Side Support VT Ablation & Other (2017/2018) STEMI (Infarct Reduction) Heart Failure (Class III) 250K U.S. Patients 100K U.S. Patients Geographies U.S. Germany Japan Rest of World 221K Patients 20K Patients 50K Patients Today / 2016 Future * Impella ECP, Impella 5.5, Impella BTR, are in development and are not approved for use or sale

29 CONCLUSION: ABIOMED EXECUTING ON THE VISION 29 Impella heart pumps are the new Standard of Care Current U.S. penetration 6% of 221,000 potential patients Multiple catalysts pending on existing products, new indications (+300,000 patients), new geographies and new products Abiomed has years of growth ahead

30 THANK YOU

31 APPENDIX

32 CLINICAL GUIDELINES FOR IMPELLA 2.5 TM 32 Protected PCI 2014 AHA/ACC Guideline for the Management of Patients With n ST-Elevation Acute Coronary Syndromes. Circulation Revascularization in Heart Failure: Class I Revascularization strategy based on degree, severity, & extent of CAD; cardiac lesions; extent of LV dysfunction; prior revascularization. PVADS: Large amount of ischemic territory/poor LV function 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. JACC High risk patients: Class IIb CLASS III: HARM without Hemodynamic support; for PCI at hospitals without on-site cardiac surgery Categories referencing Impella include Percutaneous LVAD, PVAD, n-durable MCS, TCS and percutaneous MCSD Reimbursement and coding information: Inpatient Hospital = ICD.9 Code 37.68, commonly MS-DRG 216/217 Physician = CPT codes (insertion), (removal), (repositioning) Additional Guidelines 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. JACC PCI and Cardiogenic Shock: Class I Use of Mechanical Circulatory Support: American Heart Association. Circulation 2012 Acutely decompensated heart failure patients: Class IIa 2013 Int l Society for Heart & Lung Transplantation Guidelines for Mechanical Circulatory Support. Jnl of Heart & Lung Transplantation Temporary mechanical support for patients with multi-organ failure: Class I 2013 ACCF/AHA Guideline for the Management of Heart Failure, JACC Bridge to Recovery or Bridge to Decision for patients with acute, profound hemodynamic compromise: Class IIa 2013 ACCF/AHA Guideline for the Management of ST- Elevation Myocardial Infarction. Circulation STEMI and Cardiogenic Shock: Class IIb STEMI and urgent CABG: Class IIa

33 A GROWING POPULATION APPROPRIATE FOR PROTECTED PCI TM 33 Heart failure, diabetes, advanced age, peripheral vascular disease, complex lesions, history of angina, prior surgery Patient Comorbidities Protected PCI TM Patients Complex Coronary Artery Disease Multi-vessel disease, Left Main disease Hemodynamic Compromise Depressed ejection fraction (LVEF<35%)

34 META-ANALYSIS OF COMPLETE VS. INCOMPLETE REVASCULARIZATION 33 Pooled PCI Studies Relative Risk [95% CI] p-value Mortality 0.72 [0.64, 0.81] < in patients with multivessel CAD undergoing revascularization with CABG or PCI, CR was associated with lower morbidity and mortality. MI 0.80 [0.71, 0.91] Repeat Revasc 0.72 [0.63, 0.81] < Complete revasc better Incomplete revasc better Garcia et al, JACC Vol. 62,. 16, 2013

35 REVERSE THE CARDIOGENIC SHOCK SPIRAL Impella w FDA Approved for Cardiogenic Shock Therapy Cardiogenic Shock Identifiers (Protocol elements) SBP <90 mmhg or on Inotropes/Pressors Cold, clammy, tachycardia Lactate elevated >2 mmoi/l Cardiogenic etiology evaluation EKG (STEMI / NSTEMI) Echocardiography If available, PA catheter, Cardiac Output, CPO, CI, PCWP, SvO 2 MAP End Organ Perfusion Cardiac Output Cardiac Power Output Myocardial Recovery Patients Reverse Spiral Ischemia End Organ Failure Progressive Myocardial Dysfunction Death Spiral of Cardiogenic Shock

36 IMPELLA BEST PRACTICES IN AMI CARDIOGENIC SHOCK Identify (Protocols) SBP <90 mmhg or on Inotropes/Pressors Cold, clammy, tachycardia Lactate elevated >2 mmoi/l Cardiogenic etiology evaluation EKG (STEMI / NSTEMI) Echocardiography If available, PA catheter, Cardiac Output, CPO, CI, PCWP, SvO 2 Stabilize Early Impella Support pre-pci Reduce Inotropes/Pressors Complete Revascularization PCI Guidelines based in Cardiogenic Shock Assess for Myocardial Recovery (Weaning and Transfer Protocols) Cardiac Output Cardiac Power Output Urine Output Lactate Inotropes Myocardial Recovery Recovery Escalate & Ambulate Ongoing Left heart failure Assess for Right heart failure

37 LIMITATIONS OF CONVENTIONAL THERAPY Mortality Risk with Inotropes/Vasopressors 1 N = 40 IABP-SHOCK II Randomized Controlled Trial 2 N = 600 IABP (n=301) Medical Therapy (n=299) 41.3% 39.7% 1- Samuels LE et al, J Card Surg Thiele H et al. NEJM Clinicaltrial.gov # NCT

38 Protected PCI Cardiogenic Shock DATA SUPPORTING FDA INDICATIONS Scientific Evidence Total # of Patients # of Impella Patients Recover I FDA Study ISAR Shock RCT U.S. Impella Registry Literature review 2, Total 2,981 1,123 Protect I FDA Study Protect II FDA Study U.S. Impella Registry 1, Literature review 2, Total 4,331 1,638 24,000 Patients from FDA medical device reporting (MDR) database

39 Incremental cost per life year or QALY ($thousands) IMPELLA HEART PUMPS ARE COST-EFFECTIVE (ICER) 39 $274k $175 $199k $150 $125 $100 <$100,000 Threshold (US) $75 $50 $25 $0 Impella Emergent 2 Aspirin MI CRT-P C-reactive Protein Clopidogrel Impella PROTECT II CRT-D Impella US Registry TAVR (LYG) AF ablation Impella EU Registry Dialysis (LYG) LVAD 1 DT(LYG) LVAD 2 DT(LYG) 1 1. Maini, et al. CCI, Earnshaw, et al. Arch. of Intern Med., Feldman, et al. JACC, COMPANION 4. Choudhry, et al. JACC, JUPITER 5. Chen, et al. ISPOR, 2009.CHARISMA 6. Gregory, et al. Am Health & Drug Ben, Feldman, et al. JACC, COMPANION 8. Roos, et al. J Med Econ, Reynolds, et al. ACC, Reynolds, et al. Circ Arrhythm Electrophysiol, Winkelmayer, et al. Medical Decision Making, Slaughter, et al. AHA, Russo, et al. ACC ICER: Incremental cost-effectiveness ratio. A statistic used in cost-effectiveness analysis to summarize the cost-effectiveness of a health care intervention. It is defined by the difference in cost between two possible interventions, divided by the difference in their effect.

40 IMPELLA HEART PUMP CHARACTERISTICS 40 Impella has 15 years of experience and over 35,000 U.S. patients treated with design critical for patient safety and ease of use 9Fr Catheter (9Fr in leg) Quiet, no active driveline Impeller Safety Stop, dispersion of debris Small surface area over impeller 12 fr smooth surface across valve (Impella 2.5) 14 fr smooth surface across valve (Impella CP) 6fr Standard Pigtail

41 Impella Heart Pump Papers Demonstrate Safety with Aortic Valve 41 Study Device n LOS Imaging Modality Echo findings Trauma / valve Aortic Regurgitation Cohen et al (Urgent/Elective Registry) Up to 3 days TTE Sharma et al days TTE/TEE 1 O Neill et al (Emergent Registry) Up to 18 days TTE O Neill et al PROTECT II * Up to 26 hrs TTE Burzotta et al N.A Serial TTE Dixon et al PROTECT I * Up to 2.5 hrs Serial TTE Henriques and al Up to 2 hrs Serial TTE Valgimigli and al ~ 2.5 hrs Angio Vlasselaers and al days Serial TTE Meyns and al Up to 8 days Serial TEE Siengenthaler and al Up to 10 days Serial TEE Cantena and al N.A 3D TTE / 2D TEE Catena and al Up to 19 days Serial TEE Colombo and al days Serial TEE Strecker and al days Serial TEE Jurmann and al Up to 7 days Serial TEE LOS=length of support; TEE = Trans-oesophageal echocardiogram; TTE = Trans-Thoracic Echocardiogram * PROTECT 1 and PROTECT II are FDA trials

42 ABIOMED PRINCIPLES PATIENTS FIRST 42 RECOVERING HEARTS & SAVING LIVES Recovering hearts and saving lives is the founding principle and guiding compass of our organization. This is our highest recognition of success. Recovering and preserving our patients hearts enables them to return home to their families and enjoy an improved quality of life. GROWING SHAREHOLDER VALUE Growing shareholder value rewards our investors and helps to ensure the company s financial stability, allowing for the continued pursuit of our mission. Shareholder value is driven by executing our goals and achieving positive financial results. For employees, growth of shareholder value provides financial security for our families and the pursuit of happiness for our future. LEADING IN TECHNOLOGY & INNOVATION We are committed to providing patients and health care providers with the highest quality devices and optimal cost-effective solutions. We accomplish this through the relentless exploration of new ideas and approaches that allow us to address new clinical challenges for our customers and patients. SUSTAINING A WINNING CULTURE Patients First. Our patients and customers are the motivation for all that we do and achieving our mission is dependent on their well-being. We must always act with integrity and honor and demand the best of ourselves. We work hard, have faith in each other, and have fun celebrating the patient success stories.